Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Cell Reports

Volumn 15, Issue 6, 2016, Pages 1134-1143

  Jiménez Valerio, Gabriela ^a   Martínez Lozano, Mar ^a   Bassani, Nicklas ^a   Vidal, August ^b   Ochoa de Olza, María ^a,c   Suárez, Cristina ^c   García del Muro, Xavier ^a   Carles, Joan ^c   Viñals, Francesc ^a,d   Graupera, Mariona ^e   Indraccolo, Stefano ^f   Casanovas, Oriol ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER RESISTANCE; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METABOLIC SYMBIOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, RENAL CELL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PHENOTYPE; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; EVEROLIMUS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE, NUDE; PHENOTYPE; PYRROLES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964685809     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.04.015     Document Type: Article

References (15)

1. Allen E., Miéville P., Warren C.M., Saghafinia S., Li L., Peng M.W., Hanahan D. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 2016, 15:1144-1160. this issue.
2. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
3. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49. Cancer Genome Atlas Research Network.
4. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
5. De Bock K., Mazzone M., Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat. Rev. Clin. Oncol. 2011, 8:393-404.
6. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
7. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
8. Motzer R.J., Barrios C.H., Kim T.M., Falcon S., Cosgriff T., Harker W.G., Srimuninnimit V., Pittman K., Sabbatini R., Rha S.Y., et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2014, 32:2765-2772.
9. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
10. Pisarsky L., Bill R., Fagiani E., Dimeloe S., Goosen R.W., Hagmann J., Hess C., Christofori G. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 2016, 15:1161-1174. this issue.
11. Rini B.I. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009, 115(10, Suppl):2306-2312.
12. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10:992-1000.
13. Schulze A., Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373.
14. Sonveaux P., Végran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., Diepart C., Jordan B.F., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008, 118:3930-3942.
15. Ullah M.S., Davies A.J., Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281:9030-9037.